603983 Guangdong Marubi Biotechnology
- 29.88
- +1.59+5.62%
Guangdong Marubi Biotechnology News
Marumi Co., Ltd. (603983): Non-net profit increased by 41% in Q1, and the potential of star products continues to be unleashed
1Q24's performance is better than what we expect the company to announce in 2023: revenue of 2,226 million yuan, +28.5% year over year; net profit to mother of 259 million yuan, +48.9% year on year; net profit of 188 million yuan.
Marumi Co., Ltd. (603983) Comment: 1Q24 results exceeded expectations, operating improvements expected to deliver profit margins quarter by quarter
On April 26, the company announced 4Q23 revenue of 689 million yuan, +17.2% year-on-year, net profit of 85.59 million yuan, +58% year-on-year, after deducting non-net profit of 30.76 million yuan, -34% year-on-year
Marumi Co., Ltd. (603983): Gross margin increased significantly in the first quarter, both brands simultaneously boosted sales growth
Core view The company's revenue in '23 was 2,226 billion yuan, +28.52%, net profit to mother was 259 million yuan, +48.93%, after deducting non-net profit of 188 million yuan, +38.16%. 24Q1 Revenue 6.
Marumi Co., Ltd. (603983): Revenue continues to break through, profit margins continue to be optimized
Outstanding performance in '23, profit margin increased. In '23, the company achieved revenue of 2,226 million yuan/yoy 28.52%, net profit to mother of 259 million yuan/yoy 48.93%, of which 23Q4 revenue was 6.89
Marumi Co., Ltd. (603983): 23Q4 operating profits are under pressure, and online channel operation efficiency is expected to improve
The company published its annual report for the year 23. Achieved revenue of 2,226 million yuan/yoy +28.52% in '23, net profit of 259 million yuan/yoy +48.93%, net profit of non-return to mother of 188 million yuan/yoy+
Marumi Co., Ltd. (603983): 24Q1 results exceeded expectations, gross margin reached a record high
Report guide: The company's high performance in 2023 and 24Q1 was mainly driven by Marumi's Douyin channel and sub-brand Love Fire. At the same time, gross margin continued to increase due to product structure optimization, cost reduction and efficiency improvement, etc., and profitability is expected to continue to improve in the future.
Marumi Co., Ltd. (603983): Douyin and Tmall work together to continue to grow at a high rate
Incident review: The company announced its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 2,226 billion yuan, an increase of 28.52%; realized net profit of 259 million yuan, an increase of 48.93%; achieved
Express News | Marumi Co., Ltd.: Net profit of 111 million yuan in the first quarter increased by 40.62% year-on-year
Does This Valuation Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Guangdong Marubi Biotechnology fair value estimate is CN¥21.42 Guangdong Marubi Biotechnology's CN¥27.06 share price signals that it might be
Express News | The first “frontrunner” group standard for eye cream in China was officially released, and Marumi Co., Ltd. was the first drafting unit
Aimeike (603983): Net profit maintained high growth in 23 years, product layout progressed steadily
Event: The company released its 2023 annual report. Comment: Net profit for the whole year increased 47% year on year, and gross margin remained high in 2023. The company achieved operating income of 2,869 billion yuan, an increase of 47.99% year on year, and achieved net profit to mother
Guangdong Marubi Biotechnology (SHSE:603983) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Marumi Co., Ltd. (603983.SH): Obtained a high-tech enterprise certificate
Gelonghui, Feb. 23: Marumei Co., Ltd. (603983.SH) announced that it has received a high-tech enterprise certificate jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. The certificate number is GR202344003218; the date of issue is December 28, 2023; it is valid for three years. After being certified as a high-tech enterprise in 2011, 2014, 2017, and 2020, the company was once again certified as a high-tech enterprise. This is a re-certification carried out after the validity of the company's original high-tech enterprise certificate has expired, and it will not be subject to public approval
Guangdong Marubi Biotechnology (SHSE:603983) May Have Issues Allocating Its Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expand
Marumi Co., Ltd. (603983): Revenue is expected to continue to maintain a relatively rapid growth rate
The Marumi brand regained a relatively rapid growth rate, and the Koiwa brand gained momentum. In '23, profit margin optimization, the company actively promoted online channel transformation. According to the 23-year performance forecast, the main brand Marumi's e-commerce revenue for content represented by Douyin increased by more than 100%; PL Love
Marumi Co., Ltd. (603983): The company released a performance forecast, and the main brand transformation effects continued to show that Koiho maintained a high growth rate
Event: The company released its 23-year performance forecast 1) Year 23: It is expected to achieve net profit of 3-33 billion yuan, an increase of 72%-89% over the previous year, and achieve net profit without deduction of 22-250 million yuan, an increase of 62% over the previous year
Marumi Co., Ltd. (603983) 2023 performance forecast review: Beautiful performance in 23 years, looking forward to continued high-quality growth
The company expects revenue to increase 30% + year on year in '23, net profit of 300-330 million yuan, and 72-89% year-on-year increase. Marumi Co., Ltd. announced its 2023 performance forecast. The company expects revenue growth of more than 3 in 2023
The A-share beauty care sector fluctuated and increased
Glonghui, January 24 | Reliable shares rose more than 8%, Marumi shares rose more than 7%, and Novon shares, Freda, Baiya shares, etc. followed suit.
Marumi Co., Ltd. (603983): 2023 performance slightly exceeded expectations, channel transformation product strategy continues to advance
The company released its 2023 performance forecast. Net profit for the whole year is expected to be +72% ~ 89% year-on-year, and net profit to mother of 23Q4 compared to +133% to 188% YoY. Since the performance slightly exceeded expectations, we raised our profit forecast to 20
Marumi Co., Ltd. (603983): Forecast Q4 profit increased 133-188%, net interest rate improvement exceeded expectations
Performance preview The company predicts that net profit due to mother will increase by 72%-89% year-on-year in 2023. The company issued a performance forecast. It is estimated that revenue will increase by more than 30% in 2023, and net profit to mother will increase by 300-330 million yuan, or 72% -89 million yuan
Analysis
Price Target
No Data
